A phase I/II study of lenalidomide in combination with sunitinib in patients with advanced or metastatic renal cell carcinoma.
Saved in:
| Title: | A phase I/II study of lenalidomide in combination with sunitinib in patients with advanced or metastatic renal cell carcinoma. |
|---|---|
| Authors: | Rini B; Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, Glickman Urological Institute, Cleveland. Electronic address: rinib2@ccf.org., Redman B; Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor., Garcia JA; Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, Glickman Urological Institute, Cleveland., Burris HA 3rd; Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville., Li S; Celgene Corporation., Fandi A; Celgene Corporation., Beck R; Celgene Corporation., Jungnelius U; Celgene Corporation., Infante JR; Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville. |
| Source: | Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2014 Sep; Vol. 25 (9), pp. 1794-1799. Date of Electronic Publication: 2014 Jun 08. |
| Publication Type: | Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Elsevier Country of Publication: England NLM ID: 9007735 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1569-8041 (Electronic) Linking ISSN: 09237534 NLM ISO Abbreviation: Ann Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
